AstraZeneca

#AstraZeneca #Biopharmaceuticals #Covid-19 #Immunology / Virology & Vaccines

AstraZeneca vaccine is 92% effective against Delta variant

New data from Public Health England (PHE) demonstrated AstraZeneca’s Covid-19 vaccine offers high levels of protection against the Delta variant (B.1.617.2; formerly the ‘Indian’ variant). Real world data from PHE, published as a pre-print, demonstrated two doses of AstraZeneca are 92% effective against hospitalisation due to the Delta variant and… Read More

#Covid-19 #News #Trending News

#AstraZeneca #Clinical trials #Covid-19 #Moderna #Pfizer #Research

Behind the UK Cov-Boost trial

The UK government has begun the Cov-Boost clinical trials for a booster coronavirus vaccine in a bid to test its effectiveness against the new variants of the virus. As part of the trial, seven vaccines ordered by the UK government will be tested on thousands of volunteers at random in… Read More

#Covid-19 #Exclusive Content #News

#AstraZeneca #Biotherapeutics #Drug discovery #Immuno-oncology

Biotech collaboration to accelerate prostate cancer research

Alchemab has collaborated with AstraZeneca to work on a proof-of-concept study to build understanding of the fundamental biology of prostate cancer. Under the agreement, Alchemab’s novel drug discovery platform will be used as a diagnostic tool through the identification of disease biomarkers with potential to inform the development of novel… Read More

#News

#AstraZeneca #Clinical trial #Covid-19 #Immunology / Virology & Vaccines

Oxford-AstraZeneca US vaccine trial data may be outdated

The Data and Safety Monitoring Board (DSMB) has notified the National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority (BARDA), and AstraZeneca that it is “concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial”. Trial volunteers received two standard… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Covid-19 #Drug delivery #Immunology / Virology & Vaccines

US trial data show Oxford-AstraZeneca vaccine is safe and 79% effective 

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca in the US, Chile and Peru has shown that the vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom. In the trial, which… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Biotechnology #Covid-19 #Immunology / Virology & Vaccines #Pfizer

Existing vaccines may protect against coronavirus variants

Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise or stop infection from variants that are circulating in South Africa, Brazil and elsewhere. The data suggests that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly,… Read More

#Covid-19 #News

#AstraZeneca #Big pharma #Business #Covid-19 #Life sciences #Pfizer

Why investors have their eye on the pharmaceutical sector

Andrew Aldridge, Partner at  Deepbridge Capital explains why life science sector has shot up the UK investment agenda as vaccinations are rolled out. The past twelve months have showcased the importance of medical developments like never before. Innovation in the life sciences sector has been headline news around the globe and… Read More

#Business & Investment #Covid-19 #News #Opinion

#AstraZeneca #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Pfizer

COVID-19 booster shots more likely than vaccines due to variants

Data analytics company, GlobalData says that if new SARS-CoV-2 variants continue to develop, reducing the effectiveness of COVID-19 vaccines and the natural immunity of survivors, then annual booster shots may be required for COVID-19 immunity. Johanna Swanson, Product Manager at GlobalData, said: “Of the several natural variants that have recently been… Read More

#Covid-19 #News

#AstraZeneca #Biopharmaceuticals #Drug delivery #Drug development

Aptamer Group extends AstraZeneca collaboration

UK reagents and therapeutics developer, Aptamer Group has extended its current agreement with global biopharmaceutical company AstraZeneca. This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates. Optimers… Read More

#Editor's Choice #News #Trending News

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Study

Study shows effectiveness of one dose of COVID-19 vaccine in over 80s

Interim study results show the effectiveness of one dose of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in preventing hospitalisation of people in their 80s with multiple comorbidities. The AvonCAP study results are by researchers from the University of Bristol, University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) and North Bristol… Read More

#Covid-19 #News

#AstraZeneca #Clinical trials #Covid-19 #Drug discovery #Therapeutics #Vaccines

Where are the opportunities in global drug discovery?

With COVID-19 taking centre stage in global drug discovery, Lu Rahman looks at opportunities ahead for the sector and where attention might be focussed going forward.  It is clear from the current pandemic that opportunities arise within drug discovery and development when we don’t always expect them. COVID-19 has created… Read More

#Covid-19 #Exclusive Content #Trends & Analysis